MorphoSys AG MOR
At closeAug 2, 2024, 4:00 PM EDT
52-week range unavailable
- Market cap
- 2.86B
- Revenue (ttm)
- 241.47M
- Profit margin
- -190.61%
- Shares out
- 150.65M
- Forward P/E
- -6.36
- Volume
- 19.16K
- Open
- 18.38
- Previous close
- 18.96
- Day's range
- 18.38 – 19.15
- Beta
- 0.66
- Analysts
- Hold
- Price target
- 14.16 (-25.3%)
- Earnings date
- Aug 29, 2024
Key statistics
- Enterprise value
- 1.82B
- PEG ratio
- 0.00
- Price / sales
- 11.83
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 13.10%
- Free cash flow
- 98.90M
- Total cash
- 630.77M
- Total debt
- 1.73B
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 18.46
- 200-day average
- 14.74
Analyst view
Consensus: hold
- Target (low)
- 11.60
- Target (mean)
- 14.16
- Target (high)
- 16.71
- Strong buy0
- Buy1
- Hold3
- Sell0
- Strong sell0
Next earnings
Aug 29, 2024
Expected Aug 29, 2024. Consensus EPS estimate -1.21.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 29, 2024 | Jun 1, 2024 | -0.50 | — | — | — |
| Apr 29, 2024 | Mar 1, 2024 | -0.51 | — | — | — |
| Mar 13, 2024 | Dec 1, 2023 | -0.92 | — | — | — |
| Nov 15, 2023 | Sep 1, 2023 | -0.49 | — | — | — |
| Aug 9, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 3, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2023 | Morgan Stanley | up | Underweight | Overweight |
| Sep 14, 2023 | Goldman Sachs | up | Sell | Neutral |
| Jun 21, 2023 | JMP Securities | reit | Market Outperform | Market Outperform |
| Jun 15, 2023 | Wells Fargo | init | — | Overweight |
| Jun 15, 2023 | JP Morgan | up | Underweight | Overweight |
| Jan 2, 2023 | JP Morgan | down | Neutral | Underweight |
About MorphoSys AG
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany. As of May 30, 2024, MorphoSys AG operates as a subsidiary of Novartis BidCo AG.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Germany
- Website
- morphosys.com
News
Earnings Scheduled For March 13, 2024 
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session 
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session 
Why Super Micro Computer Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Applied Digital, ESSA Pharma And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
Why JetBlue Airways Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session 
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session - 12 Health Care Stocks Moving In Monday's Intraday Session
- Dell Reports Mixed Q3 Results, Joins Marvell Technology, Super Micro Computer And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Your note
Sign in to keep a note on MOR — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 5.67% | 7,760,027 | 57.97M | Jun 29, 2023 |
| Logos Global Management LP | 0.88% | 1,200,000 | 8.96M | Jun 29, 2023 |
| Opaleye Management Inc. | 0.88% | 1,209,380 | 9.03M | Jun 29, 2023 |
| Hudson Bay Capital Management Lp | 0.44% | 597,500 | 4.46M | Jun 29, 2023 |
| Millennium Management Llc | 0.31% | 423,421 | 3.16M | Jun 29, 2023 |
| Point72 Asset Management, L.P. | 0.16% | 218,700 | 1.63M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Small Cap Stock Fund | 1.63% | 2,225,179 | 16.62M | Jun 29, 2023 |
| Price (T.Rowe) Small-Cap Value Fund | 1.14% | 1,554,800 | 11.61M | Jun 29, 2023 |
| Price (T.Rowe) Institutional Small-Cap Stock Fund | 0.88% | 1,203,913 | 8.99M | Jun 29, 2023 |
| Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 0.77% | 1,050,690 | 7.85M | Jun 29, 2023 |
| Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 0.47% | 638,100 | 4.77M | Jun 29, 2023 |
| Mutual Fund Ser Tr-AlphaCentric LifeSci Healthcare Fund | 0.14% | 185,000 | 1.38M | Jun 29, 2023 |